Timing Peptide-Based Brain Cancer Treatment to the Tumor's Biological Clock Improved Drug Uptake | Research

The takeaway

A cell-penetrating peptide nanocomplex delivering both temozolomide and the p53 gene to glioblastoma cells showed peak effectiveness when timed to specific circadian time points matching transferrin receptor and clock gene expression peaks.

Peak uptake at T8
Peptide nanocomplex uptake and p53 expression were highest at the circadian time point matching peak transferrin receptor and Per2 clock gene expression in glioma cells

What the researchers found

The WRAP5 cell-penetrating peptide functionalized with a transferrin receptor ligand (Tf) successfully co-delivered temozolomide and a p53-encoding plasmid to U87 glioma cells. Computational modeling of circadian gene expression revealed key timing windows: the transferrin receptor expression peaked at T7 and T8 time points, while clock genes Bmal1 and Per2 peaked at T16 and T8, respectively.

Confocal microscopy confirmed that intracellular uptake of the peptide nanocomplexes and p53 mRNA expression were highest at T8 — the time point coinciding with peak transferrin receptor and Per2 expression. Protein-level analysis confirmed these transcriptional changes, with T16 emerging as a favorable time point for maximizing therapeutic efficacy. The results demonstrate that synchronizing peptide nanocomplex delivery with tumor circadian biology can enhance both cellular uptake and therapeutic gene expression.

Why it matters

Glioblastoma has a median survival of about 15 months even with treatment, and temozolomide resistance is common. This study tackles two major challenges simultaneously: improving drug delivery using a peptide-based targeting system, and optimizing treatment timing using chronobiology. If tumors are most vulnerable to treatment at specific times in their biological clock cycle, timing drug administration accordingly could dramatically improve outcomes without increasing doses or side effects.

How the study worked

Researchers used a previously developed WRAP5 cell-penetrating peptide conjugated to a transferrin receptor ligand for targeted delivery of temozolomide and p53 plasmid DNA to U87 glioma cells. Circadian oscillations of clock genes (Bmal1, Per2) and the transferrin receptor were mapped using two computational models. Confocal microscopy assessed intracellular uptake at different circadian time points. mRNA and protein analysis measured p53 expression levels across the circadian cycle to identify optimal treatment windows.

What this study cannot tell us

This is entirely an in vitro study using U87 glioma cells — one of the most commonly used but least representative glioblastoma cell lines. The circadian oscillations in cultured cells may not reflect those in actual brain tumors, which are influenced by the patient's sleep-wake cycle, brain microenvironment, and blood-brain barrier. No in vivo or animal model data is presented. The blood-brain barrier, the major obstacle for glioblastoma drug delivery, was not addressed in this cell culture system.

How to read the evidence

This is an in vitro proof-of-concept study using a single glioma cell line. While the integration of peptide delivery, gene therapy, and chronobiology is innovative, all findings are from cell culture and have not been validated in animal models or clinical settings. The evidence is preliminary but conceptually strong.

When this study was published

Published in 2025, this is a very recent study at the intersection of three active research frontiers: cell-penetrating peptide therapeutics, cancer gene therapy, and chronobiology.

The bigger picture

Chronotherapy — timing treatments to the body's or tumor's biological clock — is an emerging frontier in cancer treatment. This study uniquely combines three cutting-edge approaches: cell-penetrating peptide delivery, gene therapy, and chronobiology. The concept that tumor cells have their own circadian rhythms that can be exploited for treatment timing could transform oncology. If validated in vivo, this approach could be applied to other cancers where receptor expression and drug sensitivity fluctuate with circadian rhythms.

Questions still open

Do glioblastoma tumors in living patients maintain the same circadian receptor expression patterns seen in cultured cells?
Can the WRAP5 peptide nanocomplex cross the blood-brain barrier, and would circadian timing affect its brain penetration?
Would combining this chronotherapy approach with standard radiation therapy further enhance glioblastoma treatment outcomes?

Common questions

What is a cell-penetrating peptide and how does it deliver drugs to cancer cells?

Cell-penetrating peptides (CPPs) are short peptide sequences — typically 5 to 30 amino acids — that can cross cell membranes, carrying therapeutic cargo along with them. WRAP5, used in this study, acts like a molecular Trojan horse: it wraps around the drug (temozolomide) and gene therapy payload (p53 DNA), then uses a transferrin receptor-targeting molecule to home in on glioblastoma cells specifically. Once it reaches the cancer cell, the peptide facilitates entry through the cell membrane, delivering both the chemo drug and the gene therapy directly inside.

Why does timing matter for cancer treatment?

Cancer cells, like normal cells, have internal biological clocks that cause their gene activity to rise and fall in roughly 24-hour cycles. This includes receptors on the cell surface that drugs use to enter cells. In this study, the transferrin receptor — the docking point for the peptide drug carrier — peaked at specific times. Delivering treatment when this receptor is most abundant means more drug gets inside the cancer cell. Additionally, genes involved in cell division and DNA repair fluctuate with circadian rhythms, potentially making tumors more or less vulnerable to treatment at different times of day.

Read the original research

Circadian-Tuned Peptide Drug/Gene Co-Delivery Nanocomplexes to Enhance Glioblastoma Targeting and Transfection.

International journal of molecular sciences, 26(13)

View on PubMed ↗Publisher’s paper ↗

Citation

Neves, Ana R; Vivès, Eric; Boisguérin, Prisca; Quintela, Telma; Costa, Diana. (2025). Circadian-Tuned Peptide Drug/Gene Co-Delivery Nanocomplexes to Enhance Glioblastoma Targeting and Transfection.. International journal of molecular sciences, 26(13). https://doi.org/10.3390/ijms26136130